Madrigal Pharmaceuticals, Inc.
MDGL
$531.25
-$8.64-1.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.13B | 958.40M | 740.64M | 515.55M | 317.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.13B | 958.40M | 740.64M | 515.55M | 317.38M |
| Cost of Revenue | 78.48M | 56.15M | 35.15M | 19.18M | 10.75M |
| Gross Profit | 1.05B | 902.26M | 705.50M | 496.37M | 306.64M |
| SG&A Expenses | 914.47M | 813.83M | 715.07M | 613.54M | 522.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.45B | 1.26B | 1.05B | 825.36M | 742.53M |
| Operating Income | -313.51M | -300.10M | -307.48M | -309.81M | -425.15M |
| Income Before Tax | -309.44M | -288.28M | -289.13M | -281.90M | -391.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -309.44 | -288.28 | -289.13 | -281.90 | -391.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -309.44M | -288.28M | -289.13M | -281.90M | -391.59M |
| EBIT | -313.51M | -300.10M | -307.48M | -309.81M | -425.15M |
| EBITDA | -312.00M | -298.59M | -306.01M | -308.40M | -423.84M |
| EPS Basic | -12.80 | -12.16 | -12.30 | -12.14 | -17.34 |
| Normalized Basic EPS | -7.92 | -7.52 | -7.61 | -7.59 | -10.84 |
| EPS Diluted | -12.80 | -12.16 | -12.30 | -12.14 | -17.34 |
| Normalized Diluted EPS | -7.92 | -7.52 | -7.61 | -7.59 | -10.84 |
| Average Basic Shares Outstanding | 96.55M | 95.60M | 94.70M | 93.97M | 93.16M |
| Average Diluted Shares Outstanding | 96.55M | 95.60M | 94.70M | 93.97M | 93.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |